Study:
A Non-Interventional Prospective Study of the Correlation of the Precision Therapeutics, Inc. Chemoresponse Assay With Progression-Free Survival in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer.
Rationale:
n/a
Purpose:
Chemoresponse assays (lab test) measure the effect that chemotherapy treatment has on a
patient`s cancer cells in the lab. This test has shown success in a retrospective study in
predicting how an individual patient`s tumor will respond to a given chemotherapy and how
treatment utilizing an agent that the test said that a patient`s cells would be sensitive
too corresponds to a longer progression free interval. This study will determine the ability
of two tests used to predict the success of chemotherapy in recurrent, persistent, or
refractory cancer of the ovaries, fallopian tube(s) or peritoneum by measuring how long
patients live without progression.
Study Status: Terminated
Recruiting:
n/a
| Condition |
Intervention |
Phase |
Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Neoplasms |
n/a |
N/A |
Verified by
Precision Therapeutics
October, 2012
Sponsored by: Precision Therapeutics
Information provided by: Precision Therapeutics
ClinicalTrials.gov identifier: NCT00288275
Study Type: Interventional
Study Design: Observational Model: Case-Only, Time Perspective: Prospective
Cleveland Clinic
Cleveland, Ohio 44195
United States
Thomas J Rutherford, MD., Principal Investigator
Hong Ma, MD., Study Director